

Product Data Sheet

Product Name: Cefodizime sodium

Cat. No.: GC60104

Chemical Properties

Cas. No. 86329-79-5

SMILES O=C(C(N12)=C(CSC3=NC(C)=C(CC(O[Na])=O)S3)CS[C@]2([H])[C@H](NC(/C(C4=CS C(N)=N4)=N\OC)=O)C1=O)O[Na]


Formula $C_{20}H_{18}N_6Na_2O_7S_4$ M.Wt 628.63

Solubility DMSO: 62.5 mg/mL (99.42 mM) Storage Store at -20°C

General For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the tips ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Evaluation sample solution : ship with blue ice All other available size: ship with RT, or Condition blue ice upon request.

Structure



Background

Cefodizime sodium is a third generation cephalosporin antibiotic with a broad spectrum of antibacterial activity. Cefodizime sodium has no renal toxic effect, good tolerance and immune regulation activity, and has the potential for severe infections of the respiratory and urinary tracts[1][2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Enterobacteriaceae including *Escherichia coli*, *Klebsiella pneumoniae*, *Morganella morganii*, *Proteus mirabilis*, *Proteus vulgaris*, *Shigella sonnei*, *Yersinia enterocolitica* and *Salmonella* species are all consistently sensitive to Cefodizime in vitro. Cefodizime has marginal but variable inhibitory activity against *Citrobacter* species including *Citrobacter freundii*, and *Serratia marcescens*. Cefodizime inhibits other Gram-negative bacteria including *Haemophilus influenzae*, *Moraxella catarrhalis*, *Neisseria gonorrhoeae* and *Neisseria meningitidis*[1]. Cefodizime is a bactericidal antibiotic having high affinity for penicillin-binding proteins 1A/B, 2 and 3 of *E. coli*. The in vitro concentrations of Cefodizime resulting in bactericidal activity against susceptible strains of Gram-positive and Gram-negative bacteria are generally similar to the minimum inhibitory concentrations[1].

In experimentally-induced *K. pneumoniae* respiratory tract infections in mice, Cefodizime has activity comparable to Cefotaxime and Ceftazidime, and greater than that of Cefoperazone, Latamoxef, Cefuroxime or cefazolin for 8 hours after a single subcutaneous dose of 50 mg/kg. However, unlike these cephalosporins, Cefodizime continues to demonstrate pronounced bactericidal activity for at least 48 hours after a single injection. Complete bacterial clearance from the lung is achieved within 48 hours in 50% of the mice although Cefodizime is no longer detectable in the serum[1].

[1]. Barradell LB, et al. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. *Drugs*. 1992 Nov;44(5):800-34. [2]. Hu T, et al. Probing the interaction of cefodizime with human serum albumin using multi-spectroscopic and molecular docking techniques. *J Pharm Biomed Anal*. 2015 Mar 25;107:325-32.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA